PACAP38: Emerging Drug Target in Migraine and Cluster Headache

Anne Luise Haulund Vollesen; Messoud Ashina

doi:10.1111/head.13076

PACAP38: Emerging Drug Target in Migraine and Cluster Headache

Anne Luise Haulund Vollesen, Messoud Ashina

Institut for Klinisk Medicin

14 Citationer (Scopus)

Abstract

Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine and cluster headache (CH). Mounting evidence implicates signaling molecule PACAP38 in the pathophysiology of migraine. Human provocation studies show PACAP38 induces migraine attacks in migraine patients without aura and marked and sustained dilation of extracerebral arteries. PACAP38 selectively targets the PAC1receptor making this receptor a promising candidate for targeted migraine therapy. Randomized clinical trials are warranted to pursue this possible treatment pathway. PACAP38 provocation studies in CH could elucidate possible involvement of PACAP38 in CH pathophysiology and predict efficacy of PACAP38 antagonists in this primary headache.

Originalsprog	Engelsk
Tidsskrift	Headache
Vol/bind	57
Udgave nummer	S2
Sider (fra-til)	56-63
ISSN	0017-8748
DOI	https://doi.org/10.1111/head.13076
Status	Udgivet - maj 2017

Adgang til dokumentet

10.1111/head.13076

Citationsformater

@article{9bcc8073e49b48f68dbab1f3f47c88a5,

title = "PACAP38: Emerging Drug Target in Migraine and Cluster Headache",

abstract = "Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine and cluster headache (CH). Mounting evidence implicates signaling molecule PACAP38 in the pathophysiology of migraine. Human provocation studies show PACAP38 induces migraine attacks in migraine patients without aura and marked and sustained dilation of extracerebral arteries. PACAP38 selectively targets the PAC1receptor making this receptor a promising candidate for targeted migraine therapy. Randomized clinical trials are warranted to pursue this possible treatment pathway. PACAP38 provocation studies in CH could elucidate possible involvement of PACAP38 in CH pathophysiology and predict efficacy of PACAP38 antagonists in this primary headache.",

keywords = "Cluster Headache/metabolism, Humans, Migraine Disorders/metabolism, Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism",

author = "Vollesen, {Anne Luise Haulund} and Messoud Ashina",

note = "{\textcopyright} 2017 American Headache Society.",

year = "2017",

month = may,

doi = "10.1111/head.13076",

language = "English",

volume = "57",

pages = "56--63",

journal = "Headache",

issn = "0017-8748",

publisher = "Wiley-Blackwell",

number = "S2",

}

TY - JOUR

T1 - PACAP38

T2 - Emerging Drug Target in Migraine and Cluster Headache

AU - Vollesen, Anne Luise Haulund

AU - Ashina, Messoud

PY - 2017/5

Y1 - 2017/5

N2 - Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine and cluster headache (CH). Mounting evidence implicates signaling molecule PACAP38 in the pathophysiology of migraine. Human provocation studies show PACAP38 induces migraine attacks in migraine patients without aura and marked and sustained dilation of extracerebral arteries. PACAP38 selectively targets the PAC1receptor making this receptor a promising candidate for targeted migraine therapy. Randomized clinical trials are warranted to pursue this possible treatment pathway. PACAP38 provocation studies in CH could elucidate possible involvement of PACAP38 in CH pathophysiology and predict efficacy of PACAP38 antagonists in this primary headache.

AB - Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine and cluster headache (CH). Mounting evidence implicates signaling molecule PACAP38 in the pathophysiology of migraine. Human provocation studies show PACAP38 induces migraine attacks in migraine patients without aura and marked and sustained dilation of extracerebral arteries. PACAP38 selectively targets the PAC1receptor making this receptor a promising candidate for targeted migraine therapy. Randomized clinical trials are warranted to pursue this possible treatment pathway. PACAP38 provocation studies in CH could elucidate possible involvement of PACAP38 in CH pathophysiology and predict efficacy of PACAP38 antagonists in this primary headache.

KW - Cluster Headache/metabolism

KW - Humans

KW - Migraine Disorders/metabolism

KW - Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism

U2 - 10.1111/head.13076

DO - 10.1111/head.13076

M3 - Review

C2 - 28485845

SN - 0017-8748

VL - 57

SP - 56

EP - 63

JO - Headache

JF - Headache

IS - S2

ER -

PACAP38: Emerging Drug Target in Migraine and Cluster Headache

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater